Laurion Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Laurion Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,960	Closed	-$245K	–	682
2021 Q2	$245K	Sell	8,960 -41,040	-82%	-$1.16M	﹤0.01%	628
2021 Q1	$1.45M	Hold	50,000	–	–	0.01%	457
2020 Q4	$1.41M	Hold	50,000	–	–	0.01%	374
2020 Q3	$1.47M	Hold	50,000	–	–	0.02%	350
2020 Q2	$1.51M	Hold	50,000	–	–	0.02%	350
2020 Q1	$1.49M	Buy	+50,000	New	+$1.34M	0.02%	399

Other funds holding ARQT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Laurion Capital Management's ARQT Position: Q3 2021 in Review

Laurion Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2021, closing a stake of 8,960 shares — an estimated $245K sold.

Laurion Capital Management first reported a position in ARQT in Q1 2020 and held it in 6 quarters. The position peaked at $1.51M in Q2 2020. 103 funds tracked by Wall St. Rank hold ARQT as of Q3 2021.

Laurion Capital Management reported no remaining Arcutis Biotherapeutics position as of Q3 2021 after selling out during the quarter.
Laurion Capital Management sold 8,960 Arcutis Biotherapeutics shares in Q3 2021, an estimated $245K.
Laurion Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 6 quarters.
Laurion Capital Management's Arcutis Biotherapeutics position peaked at $1.51M in Q2 2020.
103 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2021.

Based on Laurion Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.